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Introduction
The cure for thalassemia involves correcting
the genetic defect in a hematopoietic stem cell
that results in reduced or absent β-globin syn-
thesis and an excess of α-globin dimers. Intra-
cellular  precipitation  and  accumulation  of  α-
dimers results in ineffective erythropoiesis and
hemolytic anemia. Replacing the abnormal tha-
lassemic marrow with allogeneic normal or het-
erozygous  stem  cells  carrying  the  functional
gene restores appropriate β-globin chain syn-
thesis.  Eighty  to  ninety  per  cent  of  patients
transplanted  from  an  HLA-identical  sibling  or
parent  become  ex-thalassemic  after  trans-
plant.1,2 Haploidentical  hemopoietic  stem  cell
transplantation has been explored as an option
for treating patients with leukemia who lack an
HLA-identical sibling or parent donor. However,
severe graft versus host disease and high graft
failure/rejection rates have limited the applica-
tion of this transplant modality for patients with
thalassemia.  Advances  using  high  doses  of  T
cell-depleted  peripheral  blood  stem  cells
(PBSCs)  and  intensive  pre-transplant  condi-
tioning regimens have helped to overcome these
limitations. Grafts containing mega doses of en-
riched CD34+ progenitor cells can be achieved
by combining bone marrow with G-CSF-mobi-
lized PBSCs. Thereafter, T-cells can be removed
by  positive  selection  for  CD34.  Limiting  the
numbers of CD3+ cells in the graft might allow
retention of rapid engraftment kinetics provided
by the mobilized PBSCs while reducing the risk
of extensive GVHD. In this pilot study, we used a
similar  approach  involving  mega  dose  hap-
loidentical  positively  selected  CD34+ marrow
and peripheral hematopoietic stem cell trans-
plantation  to  treat  patients  with  thalassemia
who lack an HLA-identical familial or unrelated
marrow donor. Positive selection of CD34+ stem
cells results in an approximately 3-4 log reduc-
tion of CD3+ cells, which reduces the risk of
GVHD but increases the risk of graft failure.3-5
Adding a defined dose of CD3+ marrow cells to
the cellular suspension at the time of transplant
can help to reduce the graft rejection rate. In
contrast  to  positive  selection  of  stem  cells,
marrow graft depleted of CD3+ and CD19+ cells
contains significant amounts of monocytes, NK
cells, dendritic cells, precursor T-cells, and other
cell types that may play important roles in en-
graftment while accelerating the post-transplant
immune reconstitution. Therefore, in a second
prospective phase of this pilot study, we evalu-
ated the use of haploidentical CD3+/CD19+-de-
pleted  marrow  graft  combined  with  CD34-se-
lected mobilized PBSCs and CD3+ marrow cells
that were added back at the time of infusion.6,7
Here, we report the outcomes of 31 children
with thalassemia who were transplanted from
haploidentical  donors,  27  was  mothers,  two
brothers and two fathers.8,9
Graft processing and transplant
procedures
All donors received recombinant human G-
CSF 15 µg/kg/day in two daily subcutaneous bo-
luses  to  mobilize  PBSCs.  CD34+ cells  from
leukapheresis and bone marrow harvests were
select using the CliniMACS one-step procedure
(Milteny Biotech, Germany) for 14 donors. Two-
step selection (CD34 positive selection leuka-
pheresis followed by negative selection using
anti-CD3  and  anti-CD19  monoclonal  anti-
bodies) of bone marrow cells was employed for
eight donors. We attempted to suppress erythro-
poiesis  by  intensive  hypertransfusion  and
chelation. Between day -59 and day -11 before
the  transplantation,  40  mg/kg  deferoxamine
was continuously infused through a central ve-
nous catheter each 24 hours. Red cells were
transfused every 3 days to maintain the hemo-
globin level between 140 and 150 g/L (14 and 15
g/dL). During this time interval hydroxyurea 60
mg/kg daily and azathioprine 3 mg/kg daily were
administered to eradicate marrow, and growth
factors,  granulocyte  colony-stimulating  factor
and erythropoietin, were given twice weekly to
maintain stem cell proliferation in the face of
hypertransfusion, thereby facilitating the effect
of the hydroxyurea. Fludarabine was adminis-
tered at a dosage of 30 mg/m
2/d from day -17
through day -13. Starting on day -10, 14 doses of
busulfan  (BU)  1  mg/kg  were  administered
orally 3 times daily over 4 days (total dose 14
mg/kg over 4 days) in the first 17 patients, and
corresponding  dose  of  busulfan  give  intra-
venous in the following 14 patients, followed by
intravenous cyclophosphamide (CY) 50 mg/kg
daily on each of the next 4 days (total dose 200
mg/kg), and 10 mg/kg thiotepa, and 12.5 mg/kg
anti-thymocyte globulin daily from days -5 to -2,
(ATG-Fresenius S).
All patients received cyclosporine for GVHD
prophylaxis for the first two months post trans-
plantation.
Graft content
Eight  patients  received  T  cell-depleted  pe-
ripheral  blood  progenitor  cells  (CD34+ im-
munoselection) and CD3+- and CD19+-depleted
bone marrow stem cells. Median infused cell
doses  per  kilogram  of  recipient  body  weight
were  CD34+:  15.2×106 (range,  8.2-26×106);
CD3± T cells: 1.8×105; and 0.27×106/kg CD19.
Twenty-three  patients  received  CD34+ mobi-
lized  peripheral  and  bone  marrow  progenitor
cells.  Positive  selection  was  performed  using
the  CliniMACS  procedure.  The  CD34+ grafts
contained a median of 14.2×106/kg CD34+ cells
(range,  5.4-39×106/kg),  2×105/kg  CD3+ cells,
and 0.19×106/kg CD19+. No side effects were as-
sociated with graft infusion.
Results
All patients showed donor chimerism by day
14 after HSCT. Granulocytes count greater than
500/mL occurred after a median time of 13 days
(range, 11-17). Seven patients rejected their
grafts, surviving with thalassemia, 3 patients
showed early mixed chimerism, which became
persistent when observed respectively at 14, 38
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and 42 months after the transplant. In 19 cases
the transplantation was successful with com-
plete allogeneic reconstitution. There were 2
patients who died from transplantation-related
causes: one of these patients died on day +114
of Epstein-Barr virus cerebral lymphoma and
one died on day +92 from CMV pneumonia. All
the 22 cured children are not anymore transfu-
sion-dependent  with  hemoglobin  levels
ranging from 10.3 g/dL to 13.8 g/dL and have an
optimal quality of life (Figure 1).
Immunological reconstitution
Delayed immune reconstitution post trans-
plant may be associated with a variety of func-
tional and immunophenotypic abnormalities at
BM level, due to augmented local production of
inflammatory cytokines, increased T-cell activa-
tion, or intrinsic hematopoietic and stromal cell
abnormalities. After 20 days post transplant, a
significant decrease in total lymphocyte counts
and depletion of CD4+ T cells were observed. In
vivo and in vitro, hemato-lymphopoiesis occurs
in association with the complex network of cell
types  found  in  the  stroma,  including  non-
hematopoietic (fibroblasts, adipocytes, and en-
dothelial cells) and hematopoietic cells (macro -
phages and T cells). Progenitor cell growth and
differentiation depend on their interaction with
stromal cells. The prevalence of macrophage-
like cells in long-term BM culture, rather than
the typical fibroblast-like cells, suggests an al-
tered composition of the BM stroma, possibly
linked to an underlying inflammatory process
within the BM microenvironment.10-12 A central
function of stromal cells is IL-7 production. Re-
cent evidence shows that IL-7 acts as a master
regulator of T-cell homeostasis, expanding both
the naive and memory T-cell populations. Com-
pared with controls, thalassemia patients exhib-
ited altered stromal cytokine production at 20
days post transplant, characterized by decreased
IL-7 levels. We can hypothesize that the delayed
immunoreconstitution  of  the  T-cell  compart-
ment may be initially the result of altered gen-
eration of new T cells arising from hematopoi-
etic progenitor cells with the interaction of im-
paired  stromal  cell  function.  NK  CD56+bright
cells develop more rapidly than other lympho-
cytes, but CD3–CD16+ NK cells (with cytotoxic
potential) require more prolonged exposure to
maturation  factor  (IL-2)  in  the  BM.  Interest-
ingly,  we  observed  higher  percentages  of  NK
CD56+bright cells 20 days post-transplant in pa-
tients with full engraftment, suggesting a role
for donor NK cells in improved engraftment and
in prevention of rejection by an attack of the
host lympho-hematopoietic cells.
After 60 days post transplant, a significant
decrease in total lymphocyte counts, and deple-
tion of CD4+ T cells expressing predominantly
the  CD45RA+CD62L+ phenotype  were  ob-
served.  Also  the  CD4+CD45RA+CD31+ T  cell
subset was significantly reduced in our cohort,
suggesting a thymus involvement in these pa-
tients. Indeed, it is possible that the T- cell de-
fect in thalassemia patients may occur at mul-
tiple levels, including egress from thymus.
NK  CD56+bright cells  develop  more  rapidly
than  other  lymphocytes,  but  CD3–CD16+ NK
cells (with cytotoxic potential) require more
prolonged exposure to maturation factor (IL-2)
in the bone marrow.16,17 Figure 2 reported the
mixed chimerism condition in each of 3 pa-
tients.  The  recipients  with  full  donor
chimerism had 100% of CD3+ donor cells and
100% of donor NK cells, stable over time.
The  individuals  who  had  stable  mixed
chimerism, showed to have very low levels of
CD3+ donor chimerism early after transplanta-
tion that increased over time, in parallel with
high and stable levels of donor NK population,
suggesting that donor NK cells might promote
tolerance  and  donor  engraftment.14,15 The
levels of immunosuppression were uniform in
all patients. No patient developed GVHD and all
patients came off immunosoppression at the
same time.
Discussion
HSCT offers the only chance of cure for pa-
tients with thalassemia. Haploidentical trans-
plantation may extend this possibility to the
50% to 60% of the patients who lack a suitably
matched familial donor or an HLA-identical un-
related donor. The presence of fetal cells in
maternal blood and of maternal cells in fetal
blood  (fetomaternal  microchimerism)  sug-
gests  that  immunologic  tolerance  may  exist
between mother and offspring. The combina-
tion of a megadose of purified CD34 cells and
a  highly  immunomyeloablative  conditioning
regimen is crucial for overcoming the barrier
of  residual  antidonor  cytotoxic  T-lymphocyte
precursors  in  T  cell-depleted  mismatched
transplants and the addition of BMMCs (in-
cluding NK cells, mesenchymal stem cells, T
cells) to a T cell-depleted allograft may help
promote engraftment and control GVHD.13 The
reason of adding back BMMCs of 3x105/kg in
our patients was based on the assumption that
a minimal threshold of lymphocytes for devel-
oping of GVHD was 105/kg. The simultaneous
addition of BMMCs (including stem cells, NK
cells,  monocytes,  DCs,  mesenchymal  cells),
may have a potential role for immunotolerance
and engraftment. BM could be a site of T cell
priming, because the antigen is accessible for
presentation by BM DCs. In addition, an im-
portant role for CD4+ T cell on BM engraft-
ment is described, not only promoting rejec-
tion of the few host cells after the conditioning
regimen, but also allowing efficient HSC dif-
ferentiation and reconstitution.
NKCD56+bright cells  develop  more  rapidly
than other lymphocytes, but CD3–CD16+ NK
cells (with cytotoxic potential) require more
prolonged exposure to maturation factor (IL-
2) in the BM. No significant correlation has
been  observed  between  cell  doses  infused
after T cell depletion or immunologic charac-
teristics of the donors and engraftment in pa-
tients, but interestingly, we observed higher
percentages  of  NK  CD56+bright cells  only  20
days post-transplant in patients with full en-
graftment, suggesting a role for newly gener-
ated NK cells in improved engraftment and in
prevention of rejection by an attack of the host
lymphohematopoietic  cells.  The  higher  per-
centages of CD3–CD16+ in mixed chimerism
patients may have a possible role in control of
host-cell  escape  and  in  maintaining  the
chimerism condition. The recipients with full
donor  chimerism  had  100%  of  CD3+  donor
cells and 100% of donor NK cells, stable over
time. Pioneering studies by Velardi and col-
leagues  revealed  that  patients  with  acute
Article
Figure 1. Results in 31 taploidentical transplant in thalassemia.Figure 2. Mixed chimerism in 3 patients after haplo HSCT.
[page 36] [Pediatric Reports 2011; 3(s2):e13]
myelogenous leukemia transplanted from an
NK alloreactive donor benefited from higher
rates  of  engraftment  and  reduced  rates  of
GVHD. The virtual abrogation of GVHD may be
a consequence of NK cell-mediated killing of
recipient antigen-presenting cells and. In our
group, no patient showed signs of GVHD post-
transplant. The beneficial effects could also be
related  to  depletion  of  patient  antigen-pre-
senting cells and facilitation of engraftment
as a result of the killing of T cells, removing
patient  lymphohematopoietic  cells,  and  pro-
duction of growth factors required for engraft-
ment  and  for  accelerating  recovery  of
myelopoiesis.  Our  studies  may  also  suggest
NK  subset  analysis  as  a  useful  measure  of
transplant outcome.
In  conclusion,  the  transplant  protocol  de-
scribed herein, appears to be well tolerated and
effective  for  eradicating  the  hematopoietic
system in patients with thalassemia. The inci-
dences of transplant-related toxicities and se-
vere infection were low.
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